Peptide–Drug Conjugates

Peptide–drug conjugates for tumor‑specific delivery across solid tumors

Targeting an oncofetal glycan motif broadly expressed in solid tumors — with a small‑peptide vector engineered for deep tumor penetration and clinically validated linker chemistry.

• Pan-tumor targeting

  Oncofetal CSA motif is virtually absent in normal adult tissue.

• Smaller vector, better penetration

  Small-peptide format versus bulky antibodies.

• Partnership-ready

  In-vivo PoC planned in 18–24 months.